KALV
KalVista Pharmaceuticals, Inc. NASDAQ Listed Apr 9, 2015$27.00
+0.00%
vs $27.00
Mkt Cap $1.4B
52w Low $9.83
100.0% of range
52w High $27.00
50d MA $24.43
200d MA $17.09
P/E (TTM)
-7.3x
EV/EBITDA
—
P/B
14.1x
Debt/Equity
0.1x
ROE
-1065.3%
P/FCF
-8.7x
RSI (14)
86.20
ATR (14)
$0.03
Beta
-0.40
50d MA
$24.43
200d MA
$17.09
Avg Volume
3.4M
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; KVD824, an oral product candidate for the treatment of HAE; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.
55 Cambridge Parkway · Cambridge, MA 02142 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 15, 2026 | BMO | -0.38 | -0.92 | -144.5% | 26.76 | +0.1% | -0.1% | +0.1% | +0.0% | +0.1% | -0.1% | — |
| May 11, 2026 | BMO | — | — | — | 26.73 | +0.0% | -0.1% | +0.1% | +0.3% | -0.1% | -0.1% | — |
| May 7, 2026 | BMO | — | — | — | 26.72 | +0.0% | +0.0% | +0.0% | -0.1% | +0.1% | +0.3% | — |
| May 5, 2026 | BMO | -0.38 | -0.92 | -144.5% | 26.66 | +0.0% | +0.2% | +0.0% | +0.0% | +0.0% | -0.1% | — |
| Mar 24, 2026 | BMO | -0.54 | -1.01 | -87.0% | 16.46 | +4.3% | +4.1% | +0.0% | +10.6% | +2.0% | -5.0% | — |
| Nov 10, 2025 | BMO | -0.96 | -0.92 | +4.2% | 10.89 | +4.6% | +5.3% | +0.0% | +16.3% | -1.9% | +4.0% | — |
| Sep 11, 2025 | BMO | -0.91 | -1.12 | -23.1% | 14.81 | -1.4% | -5.4% | +0.0% | -2.8% | -0.9% | -0.9% | — |
| Jul 10, 2025 | BMO | -0.80 | -0.99 | -23.9% | 15.51 | -4.1% | -6.4% | +0.0% | +4.8% | -0.3% | +4.1% | — |
| Mar 12, 2025 | BMO | -0.89 | -0.92 | -3.4% | 12.45 | -0.8% | -1.6% | +0.0% | +2.9% | -0.9% | -1.0% | — |
| Dec 5, 2024 | BMO | -0.91 | -0.91 | +0.0% | 9.06 | -0.7% | +8.3% | +0.0% | -4.8% | +1.1% | -3.7% | — |
| Sep 5, 2024 | BMO | -0.95 | -0.87 | +8.4% | 12.87 | +2.1% | -4.1% | +0.0% | -3.8% | -5.6% | -4.4% | — |
| Jul 11, 2024 | BMO | -0.71 | -1.02 | -43.7% | 12.50 | +1.0% | +4.3% | +0.0% | +14.7% | +1.9% | -1.8% | — |
| Mar 11, 2024 | BMO | -0.75 | -0.84 | -12.4% | 13.10 | -1.8% | -4.7% | +0.0% | +0.0% | -0.5% | -4.0% | — |
| Dec 7, 2023 | BMO | -0.76 | -0.80 | -4.9% | 8.97 | -0.8% | -9.0% | +0.0% | +7.7% | +11.0% | +1.4% | — |
| Sep 7, 2023 | BMO | -0.83 | -0.74 | +10.8% | 10.84 | +0.9% | -4.5% | +0.0% | +1.8% | -2.1% | -2.2% | — |
| Jul 7, 2023 | AMC | -0.92 | -0.77 | +16.3% | 10.29 | +1.2% | +1.7% | -6.4% | -1.7% | +1.4% | -1.2% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 1 | H.C. Wainwright | Downgrade | Buy → Neutral | $27 | $26.66 | $26.66 | +0.0% | -0.0% | +0.0% | +0.2% | +0.0% | +0.0% |
| Mar 26 | Stifel | Maintains | Buy → Buy | — | $17.14 | $16.97 | -1.0% | +10.6% | +2.0% | -5.0% | +9.6% | -1.8% |
| Mar 26 | Citizens | Maintains | Market Outperform → Market Outperform | — | $17.14 | $16.97 | -1.0% | +10.6% | +2.0% | -5.0% | +9.6% | -1.8% |
| Mar 25 | Needham | Maintains | Buy → Buy | — | $16.46 | $17.17 | +4.3% | +4.1% | +10.6% | +2.0% | -5.0% | +9.6% |
| Jan 9 | Needham | Maintains | Buy → Buy | — | $15.82 | $18.60 | +17.6% | +6.2% | -2.4% | -8.8% | +2.0% | -1.8% |
| Jan 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.82 | $18.60 | +17.6% | +6.2% | -2.4% | -8.8% | +2.0% | -1.8% |
| Jan 6 | Needham | Maintains | Buy → Buy | — | $15.66 | $15.96 | +1.9% | +0.6% | +3.7% | -3.2% | +6.2% | -2.4% |
| Dec 4 | Needham | Maintains | Buy → Buy | — | $14.66 | $14.63 | -0.2% | +11.9% | +0.2% | +2.6% | -4.2% | +4.3% |
| Nov 11 | Citizens | Maintains | Market Outperform → Market Outperform | — | $10.89 | $11.39 | +4.6% | +5.3% | +16.3% | -1.9% | +4.0% | +9.1% |
| Sep 12 | Needham | Maintains | Buy → Buy | — | $14.81 | $14.61 | -1.4% | -5.4% | -2.8% | -0.9% | -0.9% | +3.7% |
| Sep 12 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $14.81 | $14.61 | -1.4% | -5.4% | -2.8% | -0.9% | -0.9% | +3.7% |
| Jul 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.51 | $14.88 | -4.1% | -6.4% | +4.8% | -0.3% | +4.1% | +1.4% |
| Jul 8 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $15.06 | $15.43 | +2.5% | -0.7% | +7.0% | -3.0% | -6.4% | +4.8% |
| Jul 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.06 | $15.43 | +2.5% | -0.7% | +7.0% | -3.0% | -6.4% | +4.8% |
| Jul 7 | Leerink Partners | Maintains | Outperform → Outperform | — | $11.98 | $14.02 | +17.0% | +25.7% | -0.7% | +7.0% | -3.0% | -6.4% |
| Apr 8 | Needham | Maintains | Buy → Buy | — | $11.50 | $11.56 | +0.5% | -10.3% | +4.8% | -2.6% | +9.0% | +4.0% |
| Mar 26 | Citizens Capital Markets | Maintains | Market Outperform → Market Outperform | — | $12.50 | $12.32 | -1.4% | -3.4% | +2.2% | -3.3% | -3.3% | -3.3% |
| Mar 26 | Needham | Maintains | Buy → Buy | — | $12.50 | $12.32 | -1.4% | -3.4% | +2.2% | -3.3% | -3.3% | -3.3% |
| Mar 26 | Jones Trading | Maintains | Buy → Buy | — | $12.50 | $12.32 | -1.4% | -3.4% | +2.2% | -3.3% | -3.3% | -3.3% |
| Mar 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.25 | $12.25 | +0.0% | +2.9% | -0.9% | -1.0% | -2.2% | -0.8% |
| Mar 13 | Needham | Maintains | Buy → Buy | — | $12.45 | $12.35 | -0.8% | -1.6% | +2.9% | -0.9% | -1.0% | -2.2% |
| Mar 3 | Citizens Capital Markets | Maintains | Market Outperform → Market Outperform | — | $11.40 | $11.51 | +1.0% | -4.6% | +3.7% | +3.0% | +3.2% | -0.5% |
| Dec 9 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $9.81 | $9.75 | -0.6% | -4.8% | +1.1% | -3.7% | -3.9% | -0.6% |
| Dec 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.06 | $9.00 | -0.7% | +8.3% | -4.8% | +1.1% | -3.7% | -3.9% |
| Dec 5 | Needham | Maintains | Buy → Buy | — | $9.46 | $9.69 | +2.4% | -4.2% | +8.3% | -4.8% | +1.1% | -3.7% |
| Oct 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.36 | $11.27 | -0.8% | -0.7% | -0.6% | +0.3% | -2.2% | +5.8% |
| Sep 6 | Needham | Maintains | Buy → Buy | — | $12.87 | $13.14 | +2.1% | -4.1% | -3.8% | -5.6% | -4.4% | -2.4% |
| Sep 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.87 | $13.14 | +2.1% | -4.1% | -3.8% | -5.6% | -4.4% | -2.4% |
| Jul 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.04 | $13.18 | +1.1% | +14.7% | +1.9% | -1.8% | -5.1% | +2.5% |
| Jul 12 | Needham | Maintains | Buy → Buy | — | $12.50 | $12.63 | +1.0% | +4.3% | +14.7% | +1.9% | -1.8% | -5.1% |
| Jun 18 | Needham | Maintains | Buy → Buy | — | $11.82 | $11.77 | -0.4% | -3.8% | -1.4% | +4.7% | -0.2% | -1.5% |
| May 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.17 | $12.24 | +0.6% | -0.3% | +0.1% | +0.4% | -1.1% | +0.2% |
| May 1 | Needham | Maintains | Buy → Buy | — | $11.35 | $11.35 | +0.0% | +7.3% | -0.1% | -0.3% | +0.1% | +0.4% |
| Apr 11 | Needham | Maintains | Buy → Buy | — | $11.93 | $11.87 | -0.5% | +1.4% | -1.7% | -1.3% | +1.2% | -1.9% |
| Mar 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.10 | $12.86 | -1.8% | -4.7% | +0.0% | -0.5% | -4.0% | +0.5% |
| Mar 11 | Needham | Maintains | Buy → Buy | — | $14.36 | $14.04 | -2.2% | -8.8% | -4.7% | +0.0% | -0.5% | -4.0% |
| Feb 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.85 | $14.95 | +0.7% | -3.0% | +2.5% | +0.7% | -7.1% | -5.5% |
| Feb 13 | Needham | Maintains | Buy → Buy | — | $16.04 | $15.84 | -1.2% | -7.4% | -3.0% | +2.5% | +0.7% | -7.1% |
| Sep 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.84 | $10.94 | +0.9% | -4.5% | +1.8% | -2.1% | -2.2% | -1.2% |
| Aug 22 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $10.97 | $10.97 | +0.0% | +0.3% | -0.6% | -2.9% | +3.5% | -1.5% |
| Jul 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.29 | $10.41 | +1.2% | +1.7% | -6.4% | -1.7% | +1.4% | -1.2% |
| Mar 10 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $7.35 | $7.49 | +1.9% | -5.3% | +7.6% | +2.4% | -2.9% | +0.0% |
| Feb 3 | SVB Leerink | Maintains | Outperform → Outperform | — | $7.62 | $7.54 | -1.0% | +3.3% | +2.5% | +3.2% | -4.8% | -3.3% |
| Oct 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.15 | $5.17 | +0.4% | -4.3% | +0.4% | -5.3% | -1.7% | -1.7% |
| Oct 5 | SVB Leerink | Maintains | Outperform → Outperform | — | $5.85 | $5.87 | +0.3% | -12.0% | -4.3% | +0.4% | -5.3% | -1.7% |
| Oct 4 | Needham | Maintains | Buy → Buy | — | $14.24 | $6.99 | -50.9% | -58.9% | -12.0% | -4.3% | +0.4% | -5.3% |
| Jul 8 | Needham | Maintains | Buy → Buy | — | $10.98 | $10.69 | -2.6% | +0.8% | -4.3% | +11.5% | +5.2% | -3.1% |
| Jul 8 | SVB Leerink | Maintains | Outperform → Outperform | — | $10.98 | $10.69 | -2.6% | +0.8% | -4.3% | +11.5% | +5.2% | -3.1% |
| Jun 8 | Stifel | Maintains | Buy → Buy | — | $8.85 | $8.73 | -1.4% | -5.1% | +1.8% | -2.3% | -2.3% | +2.7% |
| Mar 11 | Needham | Maintains | Buy → Buy | — | $16.38 | $16.30 | -0.5% | -6.0% | -6.6% | +0.8% | -0.4% | +6.3% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 27, 2026 | Yea Christopher | CHIEF DEVELOPMENT OFFICER | Sell | 33,800 | $26.78 | $905K | 229,918 | +0.26% | +0.00% |
| May 26, 2026 | Yea Christopher | CHIEF DEVELOPMENT OFFICER | Sell | 1,966 | $26.78 | $53K | 229,918 | -0.07% | +0.04% |
| May 26, 2026 | Audhya Paul K. | CHIEF MEDICAL OFFICER | Sell | 2,239 | $26.78 | $60K | 150,260 | -0.07% | +0.04% |
| May 26, 2026 | Sweeny Nicole | Chief Commercial Officer | Sell | 1,489 | $26.78 | $40K | 59,291 | -0.07% | +0.04% |
| May 22, 2026 | Sweeny Nicole | Chief Commercial Officer | Sell | 1,861 | $26.78 | $50K | 55,780 | -0.07% | +0.00% |
| May 22, 2026 | Yea Christopher | CHIEF DEVELOPMENT OFFICER | Sell | 2,358 | $26.78 | $63K | 228,759 | -0.07% | +0.00% |
| May 22, 2026 | Audhya Paul K. | CHIEF MEDICAL OFFICER | Sell | 2,685 | $26.78 | $72K | 147,499 | -0.07% | +0.00% |
| May 22, 2026 | Piekos Brian | Chief Financial Officer | Sell | 1,489 | $26.78 | $40K | 21,661 | -0.07% | +0.00% |
| May 22, 2026 | Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER | Sell | 10,926 | $26.78 | $293K | 479,989 | -0.07% | +0.00% |
| May 18, 2026 | Audhya Paul K. | CHIEF MEDICAL OFFICER | Sell | 1,032 | $26.76 | $28K | 143,934 | +0.15% | -0.07% |
| May 18, 2026 | Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER | Sell | 1,129 | $26.76 | $30K | 467,665 | +0.15% | -0.07% |
| May 18, 2026 | Yea Christopher | CHIEF DEVELOPMENT OFFICER | Sell | 1,108 | $26.76 | $30K | 227,367 | +0.15% | -0.07% |
| May 12, 2026 | Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER | Sell | 3,322 | $26.71 | $89K | 466,375 | -0.15% | +0.15% |
SC TO-T/A
! Medium
KalVista Pharmaceuticals, Inc. -- Tender Offer Amendment
Roche's $27.00 per share tender offer for KalVista Pharmaceuticals values the biotech company at approximately $664 million, providing shareholders with a defined exit at a significant premium.
Jun 11
SC TO-T/A
! Medium
KalVista Pharmaceuticals, Inc. -- Tender Offer Amendment
CSL Limited's tender offer to acquire KalVista Pharmaceuticals for $27.00 per share represents a significant premium for shareholders and validates the company's rare disease drug pipeline.
Jun 1
SC TO-T
!!! Very High
KalVista Pharmaceuticals, Inc. -- Tender Offer
KalVista Pharmaceuticals accepted a $27.00 per share tender offer, representing a acquisition at that valuation for the pharmaceutical company.
May 13
8-K · 5.02
!!! Very High
Alpha Cognition Inc. -- 8-K 5.02: Executive Change
Alpha Cognition Inc. (ACOG) appointed Bethany Sensenig as a director, expanding its board composition and potentially bringing new expertise to guide the company's strategic direction.
Apr 20
8-K
Unknown — 8-K Filing
KalVista's eight-month financial results and corporate update suggest material business developments; investors should review cash position, pipeline progress, and any strategic announcements that could significantly impact the biotech company's runway and stock valuation.
Mar 25
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Vr Adviser, Llc | 6,728,985 | $109M | — | Dec 2025 |
| 2 | Tang Capital Management Llc | 4,573,530 | $74M | Reduced | Dec 2025 |
| 3 | Capital World Investors | 2,808,583 | $57M | — | Mar 2026 |
| 4 | Point72 Asset Management | 2,136,940 | $43M | Reduced | Mar 2026 |
| 5 | Silverarc Capital Management, Llc | 2,427,118 | $39M | Added | Dec 2025 |
| 6 | Millennium Management | 1,912,146 | $38M | Reduced | Mar 2026 |
| 7 | Vanguard Capital Management Llc | 1,830,467 | $37M | New | Mar 2026 |
| 8 | Woodline Partners Lp | 1,509,920 | $30M | Reduced | Mar 2026 |
| 9 | Morgan Stanley | 1,400,456 | $23M | Added | Dec 2025 |
| 10 | Bank Of New York Mellon Corp | 584,347 | $12M | Reduced | Mar 2026 |
| 11 | Bank Of America Corp /de/ | 555,628 | $11M | Added | Mar 2026 |
| 12 | Barclays Plc | 537,061 | $11M | Reduced | Mar 2026 |
| 13 | Ubs Group Ag | 515,650 | $10M | Added | Mar 2026 |
| 14 | Schroder Investment Management Group | 506,743 | $9M | Reduced | Mar 2026 |
| 15 | Northern Trust Corp | 363,694 | $7M | Added | Mar 2026 |
| 16 | Vanguard Portfolio Management Llc | 362,900 | $7M | New | Mar 2026 |
| 17 | Hrt Financial Lp | 286,916 | $6M | — | Mar 2026 |
| 18 | Ishara Investments Lp | 276,750 | $6M | New | Mar 2026 |
| 19 | Atom Investors Lp | 245,993 | $5M | Reduced | Mar 2026 |
| 20 | Blue Owl Capital Holdings Lp | 215,000 | $4M | Reduced | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$1.44B
Enterprise Value
$1.15B
P/E (TTM)
-7.32x
Forward P/E
—
PEG Ratio
-0.51x
P/B
14.05x
P/S
—
P/FCF
-8.74x
EV/EBITDA
—
Shares Out
49.7M
Financials (TTM)
Revenue
$0
Net Income
-$183.4M
EBITDA
-$173.3M
Free Cash Flow
-$153.3M
Op Cash Flow
-$152.9M
EPS Basic
$-3.69
EPS Diluted
$-3.69
EPS Forward
$-1.21
Gross Margin
0.0%
Op Margin
0.0%
Net Margin
0.0%
Balance Sheet
Total Assets
$250.8M
Total Liab.
$155.4M
Total Equity
$95.4M
Cash
$187.6M
LT Debt
$0
Book Value/Sh
$1.92
Debt/Equity
0.07x
Current Ratio
5.35
Quick Ratio
5.35
Returns & Growth
ROE
-1065.3%
ROA
-53.3%
ROIC
-90.6%
Rev Growth YoY
+0.0%
EPS Growth YoY
-7.3%
Price Returns
2W
+0.4%
1M
+0.8%
3M
+65.0%
6M
+85.7%
12M
+127.7%
Technicals
52W High
$27.00
52W Low
$9.83
50d MA
$24.43
200d MA
$17.09
RSI (14)
86.20
ATR (14)
$0.03
Beta
-0.40
Avg Volume
3.4M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$31.00
High
$37.00
Low
$27.00
Median
$30.00
Data updated apr 25, 2026 5:11pm
· Source: financialmodelingprep.com